Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Galectin Therapeutics Q3 EPS $(0.14), Same YoY

Galectin Therapeutics Q3 EPS $(0.14), Same YoY

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share. This is unchanged from the same period last year.

November 14, 2022

1 minute read

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share. This is unchanged from the same period last year.

Truist Securities Maintains Buy on Penumbra, Raises Price Target to $230

September 13, 7:46 AM

Truist Securities analyst David Rescott maintains Penumbra (NYSE:PEN) with a Buy and raises the price target from $180 to $230.

July 6, 6:43 AM

Piper Sandler analyst Christopher Donat maintains PagSeguro Digital (NYSE:PAGS) with a Overweight and lowers the price target from $22 to $13.

February 6, 6:36 PM

Sony (NYSE: SONY)’s video game division experienced its best quarter since launching the PlayStation 5, according to the company’s third-quarter

August 18, 5:05 AM

UNITY Biotechnology, Inc.